JP7395517B2 - ペプチド化合物およびその治療的用途 - Google Patents

ペプチド化合物およびその治療的用途 Download PDF

Info

Publication number
JP7395517B2
JP7395517B2 JP2020573032A JP2020573032A JP7395517B2 JP 7395517 B2 JP7395517 B2 JP 7395517B2 JP 2020573032 A JP2020573032 A JP 2020573032A JP 2020573032 A JP2020573032 A JP 2020573032A JP 7395517 B2 JP7395517 B2 JP 7395517B2
Authority
JP
Japan
Prior art keywords
peptide
seq
amino acid
peptides
proline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020573032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531246A (ja
JP2021531246A5 (enExample
Inventor
エラン オヴァディア
アヴィ ベン－シモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunity Pharma Ltd
Original Assignee
Immunity Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69141375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7395517(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunity Pharma Ltd filed Critical Immunity Pharma Ltd
Publication of JP2021531246A publication Critical patent/JP2021531246A/ja
Publication of JP2021531246A5 publication Critical patent/JP2021531246A5/ja
Priority to JP2023201767A priority Critical patent/JP7682248B2/ja
Application granted granted Critical
Publication of JP7395517B2 publication Critical patent/JP7395517B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2020573032A 2018-07-11 2019-07-10 ペプチド化合物およびその治療的用途 Active JP7395517B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023201767A JP7682248B2 (ja) 2018-07-11 2023-11-29 ペプチド化合物およびその治療的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL260555 2018-07-11
IL26055518 2018-07-11
PCT/IL2019/050774 WO2020012478A2 (en) 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023201767A Division JP7682248B2 (ja) 2018-07-11 2023-11-29 ペプチド化合物およびその治療的用途

Publications (3)

Publication Number Publication Date
JP2021531246A JP2021531246A (ja) 2021-11-18
JP2021531246A5 JP2021531246A5 (enExample) 2022-07-19
JP7395517B2 true JP7395517B2 (ja) 2023-12-11

Family

ID=69141375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573032A Active JP7395517B2 (ja) 2018-07-11 2019-07-10 ペプチド化合物およびその治療的用途
JP2023201767A Active JP7682248B2 (ja) 2018-07-11 2023-11-29 ペプチド化合物およびその治療的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023201767A Active JP7682248B2 (ja) 2018-07-11 2023-11-29 ペプチド化合物およびその治療的用途

Country Status (21)

Country Link
US (2) US11912790B2 (enExample)
EP (2) EP4566617A3 (enExample)
JP (2) JP7395517B2 (enExample)
KR (1) KR102880543B1 (enExample)
CN (1) CN112351989B (enExample)
AU (2) AU2019300567B2 (enExample)
BR (1) BR112020024748A2 (enExample)
CA (1) CA3100961A1 (enExample)
CO (1) CO2021001290A2 (enExample)
EA (1) EA202190249A1 (enExample)
ES (1) ES3026158T3 (enExample)
HR (1) HRP20250746T1 (enExample)
HU (1) HUE072141T2 (enExample)
IL (2) IL280101B2 (enExample)
MX (1) MX2021000264A (enExample)
PL (1) PL3820882T3 (enExample)
RS (1) RS66946B1 (enExample)
SG (1) SG11202012773QA (enExample)
UA (1) UA130911C2 (enExample)
WO (1) WO2020012478A2 (enExample)
ZA (1) ZA202100587B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7395517B2 (ja) 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド ペプチド化合物およびその治療的用途
IL272074B2 (en) * 2020-01-15 2024-12-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204340A1 (en) 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
JP2008510796A (ja) 2004-08-23 2008-04-10 イエダ リサーチ アンド デベロップメント カンパニー リミテッド ストレス応答を媒介するためのペプチド阻害剤
US20160038571A1 (en) 2014-08-06 2016-02-11 Brown University Method and compositions for treatment of calcineurin-related diseases
JP2016516734A (ja) 2013-03-18 2016-06-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム オートファジー誘導ペプチド類似体

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
JPS4843906B1 (enExample) * 1970-08-11 1973-12-21
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6432407B1 (en) * 1995-12-12 2002-08-13 Takara Shuzo Co., Ltd. Antigenic protein originating in malassezia
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
US6861256B2 (en) * 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
GB9711148D0 (en) * 1997-05-31 1997-07-23 Peptide Therapeutics Ltd Human MAFA
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
EP1843779A2 (en) * 2005-02-01 2007-10-17 Attenuon, LLC Compositions containing the anti-angiogenic phscn-peptide
US7704953B2 (en) 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
JP2007228925A (ja) * 2006-03-02 2007-09-13 Kaneka Corp 新規酸化酵素及びそれを用いたグリオキサールの製造方法
JP5351495B2 (ja) * 2008-11-05 2013-11-27 国立大学法人東北大学 スーパーオキシドディスムターゼを用いるアセトアルデヒド分解方法
WO2011033511A1 (en) * 2009-09-17 2011-03-24 Ramot At Tel-Aviv University Ltd. Peptides for the treatment of oxidative stress related disorders
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
EP2593595B1 (en) * 2010-07-16 2020-03-11 Avantgen, Inc. Novel peptides and uses thereof
WO2012087964A1 (en) * 2010-12-23 2012-06-28 Codexis, Inc. Gene disruptants producing fatty acyl-coa derivatives
EP3263127B1 (en) 2011-05-23 2019-08-21 Yeda Research and Development Co. Ltd Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US20140271666A1 (en) * 2013-03-14 2014-09-18 Immune Pharmaceuticals Ltd. Use of anti-eotaxin antibodies for treating inflammatory bowel disease
US20160039877A1 (en) * 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
HUE049261T2 (hu) * 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik
CA3172682A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
WO2017011338A1 (en) 2015-07-10 2017-01-19 President And Fellows Of Harvard College Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use
JP7395517B2 (ja) 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド ペプチド化合物およびその治療的用途
IL272074B2 (en) 2020-01-15 2024-12-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040204340A1 (en) 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
JP2008510796A (ja) 2004-08-23 2008-04-10 イエダ リサーチ アンド デベロップメント カンパニー リミテッド ストレス応答を媒介するためのペプチド阻害剤
JP2016516734A (ja) 2013-03-18 2016-06-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム オートファジー誘導ペプチド類似体
US20160038571A1 (en) 2014-08-06 2016-02-11 Brown University Method and compositions for treatment of calcineurin-related diseases

Also Published As

Publication number Publication date
AU2024278477B2 (en) 2026-07-09
WO2020012478A2 (en) 2020-01-16
UA130911C2 (uk) 2026-06-17
IL317252A (en) 2025-01-01
SG11202012773QA (en) 2021-01-28
BR112020024748A2 (pt) 2021-03-23
JP2021531246A (ja) 2021-11-18
HRP20250746T1 (hr) 2025-08-15
CN112351989B (zh) 2024-03-26
EP4566617A2 (en) 2025-06-11
KR102880543B1 (ko) 2025-11-04
AU2019300567B2 (en) 2024-09-19
EP4566617A3 (en) 2025-10-01
IL280101B2 (en) 2025-05-01
CN112351989A (zh) 2021-02-09
EA202190249A1 (ru) 2021-05-21
WO2020012478A3 (en) 2020-02-20
HUE072141T2 (hu) 2025-10-28
PL3820882T3 (pl) 2025-08-11
US11912790B2 (en) 2024-02-27
US20210261615A1 (en) 2021-08-26
ES3026158T3 (en) 2025-06-10
US20240190919A1 (en) 2024-06-13
AU2024278477A1 (en) 2025-01-30
IL280101A (en) 2021-03-01
MX2021000264A (es) 2021-05-12
CA3100961A1 (en) 2020-01-16
EP3820882A2 (en) 2021-05-19
CO2021001290A2 (es) 2021-02-26
AU2019300567A1 (en) 2021-02-25
ZA202100587B (en) 2022-07-27
RS66946B1 (sr) 2025-07-31
EP3820882B1 (en) 2025-04-02
IL280101B1 (en) 2025-01-01
JP2024026217A (ja) 2024-02-28
JP7682248B2 (ja) 2025-05-23
KR20210045397A (ko) 2021-04-26
EP3820882C0 (en) 2025-04-02

Similar Documents

Publication Publication Date Title
US10308926B2 (en) Stablized EZH2 peptides
JP7682248B2 (ja) ペプチド化合物およびその治療的用途
AU2016232833A1 (en) Selective Mcl-1 binding peptides
US12466853B2 (en) Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
JP7809060B2 (ja) ペプチド化合物およびそれを用いる疾患の治療方法
WO2019090015A1 (en) Peptidic materials that traffic efficiently to the cell cytosol and nucleus
EP2578226B1 (en) Peptide for treating amyotrophic lateral sclerosis
RU2812775C2 (ru) Пептидные соединения и их терапевтическое применение
EA044784B1 (ru) Пептидные соединения и способы лечения заболеваний с их использованием
EA046208B1 (ru) Пептидные соединения и их терапевтическое применение
EA051325B1 (ru) Пептидные соединения и их терапевтическое применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231129

R150 Certificate of patent or registration of utility model

Ref document number: 7395517

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150